University medical center Ljubljana, University Children's Hospital Ljubljana, Slovenia
Welcome,         Profile    Billing    Logout  
 0 Trials 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
maja, Cesen
HR-NBL2, NCT04221035 / 2019-001068-31: High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Recruiting
3
800
Europe, RoW
Vincristine, L01CA02, Carboplatin, LO1XA02, Etoposide, L01CB01, Vindesine, L01CA03, Dacarbazine, L01AX04, Ifosfamide, Doxorubicin, L01DB01, Busulfan, L01AB01, Melphalan, L01AA03, Thiotepa, L01AC01, Radiotherapy, Dinutuximab Beta, L01XC16, Cisplatin, L01XA01, Temozolomide 100 MG, Irinotecan, Cyclophosphamid
Gustave Roussy, Cancer Campus, Grand Paris, PHRC, Solving Kids' Cancer Europe, Neuroblastoma UK, , BSPHO, Instituto de Investigación Sanitaria La Fe, Deutsche Krebshilfe
High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
11/26
11/32
Hidalgo, Laura Garcia
HR-NBL2, NCT04221035 / 2019-001068-31: High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Recruiting
3
800
Europe, RoW
Vincristine, L01CA02, Carboplatin, LO1XA02, Etoposide, L01CB01, Vindesine, L01CA03, Dacarbazine, L01AX04, Ifosfamide, Doxorubicin, L01DB01, Busulfan, L01AB01, Melphalan, L01AA03, Thiotepa, L01AC01, Radiotherapy, Dinutuximab Beta, L01XC16, Cisplatin, L01XA01, Temozolomide 100 MG, Irinotecan, Cyclophosphamid
Gustave Roussy, Cancer Campus, Grand Paris, PHRC, Solving Kids' Cancer Europe, Neuroblastoma UK, , BSPHO, Instituto de Investigación Sanitaria La Fe, Deutsche Krebshilfe
High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
11/26
11/32

Download Options